Spero Therapeutics, Inc. — Director's Dealing 2017

Dec 15, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2017-12-13

Reporting Person: Sendek Joel (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-13	Stock Option (Right to Buy)	$11.63	A	27795	Acquired	2027-12-12	Common Stock (27795)	Direct

Footnotes

F1: The shares underlying this option vest as to 25% on December 13, 2018, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.